Miransertib is a selective Akt inhibitor currently in phase Ib clinical trials for the treatment of lymphoma, breast and endometrial cancers, and tumors with Akt or phosphoinositide 3-kinase (PI3K) mutations. Here, AKT1 is linked to endometrial cancer.